We read with interest the methods and results of the LIMIT-1 trial regarding primary imiquimod treatment for lentigo maligna (LM) in the journal.1 We applaud the authors for using histopathology from a resective specimen as the reference standard.
This article is protected by copyright. All rights reserved.
http://ift.tt/2o78Ccp
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου